Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Associate

Erika J. Pey

Goodwin Procter

main

Pey Erika

Goodwin Associate Erika Pey, from Boston, practices in Business Law with an emphasis on tax.

Erika J. Pey

Areas of Practice

Professional Activities

Credentials

Education

JD2022

BS2019

Admissions

Bars

Related Content

Current Issues for Qualified Small Business Stock — How New R&E Expensing Rules Could Hurt Your QSBS Status, and Why Cash Management Changes Likely Won’t

Flagship Pioneering and Pfizer Partner to Accelerate Development of Innovative Medicines Targeting Unmet Needs with $100 Million Combined Commitment

Division of Project Frog Acquired By Industrialized Construction Solutions

GreenLight Biosciences to be Acquired in a Go-Private Transaction by a Consortium Led by Fall Line Endurance Fund

iLearningEngines to List on NASDAQ via Merger with Arrowroot Acquisition Corp.

Goodwin’s Life Sciences and Capital Markets Teams Advise Avadel Pharmaceuticals in Three Major Company Transactions

Nimbus Therapeutics Announces Sale of Allosteric Tyk2 Inhibitor Program to Takeda for $4 Billion Upfront and up to $6 Billion Total

Tax